MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$11,694K
Free Cash flow
-$27,911K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from exercise of warran...
Non-cash interest expense relate...
Deferred revenue
Others
Negative Cash Flow Breakdown
Net loss
Non-cash royalty revenue
Prepaids and other assets
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Paid-in-kind interest on long-term debt
-
107
4,580
4,406
Net loss
-25,196
61,831
-31,333
-53,180
Non-cash loss on extinguishment of debt and exchange transaction
-
0
0
0
Non-cash royalty revenue
18,481
14,635
16,359
24,061
Depreciation expense
27
26
26
53
Accretion and amortization of premiums and discounts on investments
-
0
-
-
Amortization of debt issuance costs and discounts
589
641
847
1,519
Non-cash interest expense related to the revenue interest liability
-
0
0
0
Non-cash interest expense related to the royalty sale liability
13,894
16,211
14,637
26,363
Deferred revenue
-
3,798
8,366
13,795
Stock-based compensation expense
2,502
2,387
2,349
5,134
Accounts receivable
-7,838
21,210
11,234
27,604
Prepaids and other assets
17,338
8,906
6,176
15,718
Inventories
-915
-3,415
-5,927
19,975
Other long-term liabilities
-
1,303
0
7,436
Deferred revenue
9,054
-
-
-
Accounts payable
3,338
-12,445
2,901
30,462
Other accrued liabilities
-4,864
12,720
21,183
-2,680
Net cash used in operating activities
-27,722
45,243
-4,286
-54,050
Proceeds from sales/maturities of investments
-
0
-
-
Purchase of property and equipment
189
0
0
0
Net cash used in investing activities
-189
0
0
0
Proceeds from royalty sale liability
-
0
0
0
Payment of royalty sale liability issuance costs
-
0
0
-
Repurchase or principal payment of revenue interest liability
-
0
0
0
Payments on revenue interest liability
-
0
0
0
Proceeds from credit agreement, net of issuance costs
-
0
-
-
Proceeds from issuance of convertible notes, net of issuance costs
-
0
-
-
Proceeds from exercise of common stock options
-
-
141
0
Repayment of convertible notes
-
54,912
-
-
Proceeds from issuance of common stock, net of issuance costs
-
72,596
0
0
Proceeds from issuance of common stock from atm program, net of issuance costs
-
2,027
10,531
2,850
Proceeds from exercise of warrants, net of issuance costs
16,217
10,348
0
0
Payment of issuance costs
0
0
0
7,500
Other financing activities
-
244
-
-
Net cash provided by (used in) financing activities
16,217
30,162
10,672
-4,650
Net decrease in cash and cash equivalents
-11,694
75,405
6,386
-58,700
Cash and cash equivalents at beginning of period
167,852
92,447
144,761
-
Cash and cash equivalents at end of period
156,158
167,852
92,447
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
warrants, net of issuance...
$16,217K
Net cash provided by
(used in) financing...
$16,217K
Net decrease in cash
and cash...
-$11,694K
Canceled cashflow
$16,217K
Non-cash interest
expense related to the...
$13,894K
Deferred revenue
$9,054K
Accounts receivable
-$7,838K
Accounts payable
$3,338K
Stock-based compensation
expense
$2,502K
Inventories
-$915K
Amortization of debt issuance
costs and discounts
$589K
Depreciation expense
$27K
Net cash used in
operating activities
-$27,722K
Canceled cashflow
$38,157K
Net cash used in
investing activities
-$189K
Net loss
-$25,196K
Non-cash royalty revenue
$18,481K
Prepaids and other assets
$17,338K
Other accrued
liabilities
-$4,864K
Purchase of property and
equipment
$189K
Buy us a coffee
Esperion Therapeutics, Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR)